DK0600930T3 - Diagnose og behandling af autoimmune sygdomme - Google Patents

Diagnose og behandling af autoimmune sygdomme

Info

Publication number
DK0600930T3
DK0600930T3 DK92916542T DK92916542T DK0600930T3 DK 0600930 T3 DK0600930 T3 DK 0600930T3 DK 92916542 T DK92916542 T DK 92916542T DK 92916542 T DK92916542 T DK 92916542T DK 0600930 T3 DK0600930 T3 DK 0600930T3
Authority
DK
Denmark
Prior art keywords
diagnosis
treatment
autoimmune diseases
mhc class
antigen
Prior art date
Application number
DK92916542T
Other languages
Danish (da)
English (en)
Inventor
Denise L Faustman
Original Assignee
Denise L Faustman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denise L Faustman filed Critical Denise L Faustman
Application granted granted Critical
Publication of DK0600930T3 publication Critical patent/DK0600930T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK92916542T 1991-08-02 1992-07-28 Diagnose og behandling af autoimmune sygdomme DK0600930T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73987891A 1991-08-02 1991-08-02
US81051791A 1991-12-19 1991-12-19
PCT/US1992/006248 WO1993002690A1 (fr) 1991-08-02 1992-07-28 Diagnostic et traitement de maladies auto-immunes

Publications (1)

Publication Number Publication Date
DK0600930T3 true DK0600930T3 (da) 2002-12-02

Family

ID=27113589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92916542T DK0600930T3 (da) 1991-08-02 1992-07-28 Diagnose og behandling af autoimmune sygdomme

Country Status (9)

Country Link
US (1) US5538854A (fr)
EP (2) EP0600930B1 (fr)
JP (2) JPH06510903A (fr)
AT (1) ATE225397T1 (fr)
CA (1) CA2114647A1 (fr)
DE (1) DE69232798T2 (fr)
DK (1) DK0600930T3 (fr)
ES (1) ES2181676T3 (fr)
WO (1) WO1993002690A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2158455C (fr) * 1993-03-17 2003-05-27 Nicholas P. Restifo Chimeres immunogenes comportant des sequences d'acides nucleiques codant pour les peptides de la sequence du signal du reticule endoplasmique et au moins un autre peptide, et leurs ustilisations dans les vaccins et le traitement des maladies
WO1995006718A2 (fr) * 1993-09-03 1995-03-09 Viagene, Inc. Procede de suppression de la reponse auto-immune
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US5792604A (en) * 1996-03-12 1998-08-11 University Of British Columbia Method of identifying MHC-class I restricted antigens endogenously processed by cellular secretory pathway
AU773591B2 (en) * 1996-08-23 2004-05-27 University Of Florida Research Foundation, Inc. Materials and methods for detection and treatment of immune system dysfunctions
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
SE521031C2 (sv) * 1999-05-05 2003-09-23 Srinivas Uppugunduri Nya specifika inhibitorer av akut och kronisk inflammation
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
US20030044420A1 (en) * 1999-09-24 2003-03-06 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
GB0305796D0 (en) 2002-07-24 2003-04-16 Micromass Ltd Method of mass spectrometry and a mass spectrometer
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
EP3355914B1 (fr) 2015-09-29 2024-03-06 The General Hospital Corporation Une composition comprenant bcg pour réduire le cholesterol.
KR20240095471A (ko) 2016-05-13 2024-06-25 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608608A1 (de) * 1985-06-18 1986-12-18 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von autoimmunerkrankungen, viruserkrankungen und malignen erkrankungen des menschen in niedriger dosierung
DE68928183T2 (de) * 1989-03-03 1998-01-08 Univ California Klasse i-mhc-modulation von oberflächenrezeptoraktivität

Also Published As

Publication number Publication date
EP0600930A1 (fr) 1994-06-15
CA2114647A1 (fr) 1993-02-18
US5538854A (en) 1996-07-23
EP0600930B1 (fr) 2002-10-02
JPH06510903A (ja) 1994-12-08
DE69232798T2 (de) 2003-07-24
EP1298203A2 (fr) 2003-04-02
DE69232798D1 (de) 2002-11-07
EP0600930A4 (fr) 1995-01-25
ES2181676T3 (es) 2003-03-01
WO1993002690A1 (fr) 1993-02-18
ATE225397T1 (de) 2002-10-15
EP1298203A3 (fr) 2004-01-21
JP2005179371A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
DK0600930T3 (da) Diagnose og behandling af autoimmune sygdomme
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
EP0671920A4 (fr) Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih.
DE69226197D1 (de) Hämoglobine als arzneimittelabgabesystem
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FR2703254B1 (fr) Dispositif de traitement thérapeutique d'un tissu pathologique, comportant un cathéter .
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
KR920019342A (ko) 골질환 치료제
DE69108332D1 (de) Nadelvorrichtung für medizinische Zwecke.
DK0497858T3 (da) Middel til at tage terapeutiske elastiske strømperpå
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DK0522091T3 (da) Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose
NO175023C (no) Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering
DE69029575D1 (de) Ozongas verwendende medizinische behandlungsvorrichtung
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
FI933291A (fi) Foerfarande foer paovisning av anti-rna-antikroppar
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
SE7700626L (sv) Patientstol for ltandbehandling
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE69011857D1 (de) Verwendung von GnRH-analog zur Herstellung eines Arzneimittels zur Behandlung von Motilitätsstörungen.
DE3679255D1 (de) Behandlung chronischer entzuendungskrankheiten.
NO891256L (no) Apparat for medisinsk diagnose.
Shepherd, RC & Kinmonth Skin preparations and towelling in prevention of wound infection
MCCALL 15ritisb~ enical association Jaems.